TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30608864

Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 298

Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: IKDC
Number of subjects: 298
Study: 27695944

Group type: EXPERIMENTAL
Intervention: Topical administration of 9 mg of sodium hyaluronate in 3 mL of a 0.9% sodium saline solution
Number of subjects: 103

Group type: COMPARATOR
Intervention: Normal 0.9% sodium chloride saline solution
Number of subjects: 103
Study: 24378515

Group type: EXPERIMENTAL
Intervention: Nighttime lower extremity splints
Number of subjects: 46

Group type: COMPARATOR
Intervention: Liner only
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (splint and liner)
Number of subjects: 46
Study: 25204290

Group type: EXPERIMENTAL
Intervention: Comprehensive therapy based on traditional Chinese medicine (TCM) patterns including Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules along with conventional western medicine.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Conventional western medicine (control group).
Number of subjects: 136
Study: 21756153

Group type: EXPERIMENTAL
Intervention: CsA + CBD ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: CsA + emollient
Number of subjects: 60
Study: 19617379

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate 50 mg kg(‐1)
Number of subjects: 32
Study: 18154123

Group type: EXPERIMENTAL
Intervention: Intraoperative bolus-assisted administration of 5-fluorouracyl
Number of subjects: 0
Study: 15152108

Group type: EXPERIMENTAL
Intervention: Exercise intervention (education and aerobic exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Relaxation intervention (education and relaxation)
Number of subjects: 0
Study: 11295634

Group type: EXPERIMENTAL
Intervention: Chemoprevention trials
Number of subjects: 0
Study: 9924299

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1%
Number of subjects: 73

Group type: COMPARATOR
Intervention: NAAGA 4.9%
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Lodoxamide 0.1% and NAAGA 4.9%
Number of subjects: 73
Study: 7800739

Group type: EXPERIMENTAL
Intervention: 0.7 mg nicotine cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.5 mg nicotine cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1 mg nicotine cigarette (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (0.1 mg, 0.7 mg, 1.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.7 mg and 1.5 mg groups
Number of subjects: 0
Study: 3142197

Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.05 mg to 0.035 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.025 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 30977089

Group type: EXPERIMENTAL
Intervention: Chromium and carnitine co-supplementation (200 μg/day chromium picolinate plus 1000 mg/day carnitine)
Number of subjects: 54
Study: 30742692

Group type: EXPERIMENTAL
Intervention: Continuous endurance training (ET)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (CO)
Number of subjects: 80
Study: 28535933

Group type: EXPERIMENTAL
Intervention: Oseltamivir + Azithromycin (500 mg/day for 5 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oseltamivir (Control)
Number of subjects: 50
Study: 25496141

Group type: EXPERIMENTAL
Intervention: FTC/TDF
Number of subjects: 65

Group type: COMPARATOR
Intervention: ZDV/3TC
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: FTC/TDF (among subjects with lipoatrophy)
Number of subjects: 65

Group type: COMPARATOR
Intervention: ZDV/3TC (among subjects with lipoatrophy)
Number of subjects: 65
Study: 23899426

Group type: EXPERIMENTAL
Intervention: Stress imagery
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neutral imagery
Number of subjects: 64
Study: 21885896

Group type: EXPERIMENTAL
Intervention: Resistive Vibration Exercise (RVE)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistive Exercise (RE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Exercise (Control)
Number of subjects: 24
Study: 18341664

Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1% twice daily for 5 days
Number of subjects: 213

Group type: COMPARATOR
Intervention: Topical placebo ointment
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment 1%
Number of subjects: 213
Study: 16182424

Group type: EXPERIMENTAL
Intervention: Blurred images of living things
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blurred images of nonliving things
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear images of living things
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clear images of nonliving things
Number of subjects: 0
Study: 14499029

Group type: EXPERIMENTAL
Intervention: Naturopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study: 10949229

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment at 32 weeks gestation
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ultrasound assessment at both 28 and 32 weeks gestation
Number of subjects: 141
Study: 8985529

Group type: EXPERIMENTAL
Intervention: Protein energy malnutrition (measured by MUAC < 80%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Low intake of beta-carotene-rich and vitamin A-containing foods
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: General dietary improvement with increased consumption of dietary vitamin A
Number of subjects: 124
Study: 1614990

Group type: EXPERIMENTAL
Intervention: WHT dietary intervention program
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Attendance at educational sessions
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Adherence to the diet during the trial
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Baseline percentage of energy from dietary fat
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: College education
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Feelings of deprivation
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Costliness of the diet in time and money
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Development of a distaste for fat
Number of subjects: 448
Study: 6730447

Group type: EXPERIMENTAL
Intervention: Herbazol
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Biomet
Number of subjects: 61
Study: 2874823

Group type: EXPERIMENTAL
Intervention: ICI 162,846 0.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 162,846 1.0 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 162,846 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 162,846 5.0 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29483246

Group type: EXPERIMENTAL
Intervention: Restoration of vacant lots
Number of subjects: 445
Study: 26878257

Group type: EXPERIMENTAL
Intervention: Error-based progression style during balance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Repetition-based progression style during balance training
Number of subjects: 28
Study: 24721143

Group type: EXPERIMENTAL
Intervention: Combination of motivational and volitional strategies to promote walking
Number of subjects: 582

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 582
Study: 23817284

Group type: EXPERIMENTAL
Intervention: Medplanner with care coordination
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: MD.2 medication-dispensing machine with care coordination
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 414
Study: 20639023

Group type: EXPERIMENTAL
Intervention: Drug therapy plus behavioral training (oxybutynin with pelvic floor muscle training and urge suppression techniques)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drug therapy alone (oxybutynin)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Drug therapy plus behavioral training
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drug therapy alone
Number of subjects: 64
Study: 18685512

Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0
Study: 16618656

Group type: EXPERIMENTAL
Intervention: Topical decongestants (nafazoline and epinephrine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14583062

Group type: EXPERIMENTAL
Intervention: Chronomodulated infusion of oxaliplatin, fluorouracil and folinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-rate infusion of oxaliplatin, fluorouracil and folinic acid
Number of subjects: 0
Study: 10770736

Group type: EXPERIMENTAL
Intervention: Health-risk appraisal
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Interactive video
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard clinic care alone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Targeted situational behaviors
Number of subjects: 400
Study: 8863366

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole plus amikacin (TMP/SMZ plus AMI)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 217
Study: 1628634

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Thiopentone and Ketamine combinations
Number of subjects: 150
Study: 6084124

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ), 50 mg twice daily
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Guanabenz, 4 to 32 mg twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (withdrawal of guanabenz)
Number of subjects: 45
Study: 31451954

Group type: EXPERIMENTAL
Intervention: Eccentric high-intensity cycling (ECC-H: 100% POmax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Concentric moderate-intensity cycling (CONC-M: 50% POmax)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Eccentric moderate-intensity cycling (ECC-M: 50% POmax)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All exercises (including ECC-H, ECC-M, and CONC-M)
Number of subjects: 10
Study: 30065939

Group type: EXPERIMENTAL
Intervention: LH‐RHa therapy followed by a second orchidopexy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Surgery only (control)
Number of subjects: 10
Study: 26176708

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/25 mg
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: OLM/AML/HCTZ 40/10/12.5 mg
Number of subjects: 808

Group type: COMPARATOR
Intervention: OLM/AML 40/10 mg
Number of subjects: 808
Study: 24810493

Group type: EXPERIMENTAL
Intervention: S-1/carboplatin
Number of subjects: 229

Group type: COMPARATOR
Intervention: paclitaxel/carboplatin
Number of subjects: 229
Study: 23155342

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg daily for 8 weeks
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 20233513

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels within 48 h of admission in patients who died during hospitalization (n=5)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) levels within 48 h post-admission in patients who died within 6 months (n=9)
Number of subjects: 77
Study: 18559039

Group type: EXPERIMENTAL
Intervention: Head down posture during showering
Number of subjects: 40

Group type: COMPARATOR
Intervention: Head up posture during showering
Number of subjects: 40
Study: 16022063

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 60
Study: 11774064

Group type: EXPERIMENTAL
Intervention: Combined strength and endurance training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 9519219

Group type: EXPERIMENTAL
Intervention: Rebreathing method (RB) for TLCO measurement
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single-breath method (SB) for TLCO measurement
Number of subjects: 35
Study: 8124481

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Insulin (control)
Number of subjects: 14
Study: 2642566

Group type: EXPERIMENTAL
Intervention: BCG and VCN-modified autologous tumour cells (18 vaccinations over 2 years)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (not receiving immunotherapy)
Number of subjects: 301
Study: 5649

Group type: EXPERIMENTAL
Intervention: Nalorphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study: 30958047

Group type: EXPERIMENTAL
Intervention: Wetsuit
Number of subjects: 33

Group type: COMPARATOR
Intervention: Swimsuit
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Swimming Flume
Number of subjects: 33
Study: 30261955

Group type: EXPERIMENTAL
Intervention: Post-randomization lower extremity revascularization (LER)
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Surgical lower extremity revascularization
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Endovascular lower extremity revascularization
Number of subjects: 13885
Study: 27374805

Group type: EXPERIMENTAL
Intervention: German Strengthening Families Programme 10-14 (SFP 10-14) consisting of seven sessions and four booster-sessions
Number of subjects: 292

Group type: COMPARATOR
Intervention: Minimal intervention on parenting (Control)
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: German Strengthening Families Programme 10-14 (SFP 10-14)
Number of subjects: 292
Study: 24194580

Group type: EXPERIMENTAL
Intervention: Integration of social information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integration of individual with social information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulatory role of left inferior prefrontal cortex
Number of subjects: 0
Study: 21464152

Group type: EXPERIMENTAL
Intervention: Facemask combined with Le Fort I osteotomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Traditional rapid palatal expansion and FM therapy
Number of subjects: 32
Study: 19619795

Group type: EXPERIMENTAL
Intervention: Surgical pulmonary vein isolation (SPVI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cox maze procedure
Number of subjects: 60
Study: 17312278

Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE) + CD133(+) bone marrow stem cell (BMSC) administration
Number of subjects: 13

Group type: COMPARATOR
Intervention: Portal vein embolization (PVE) alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE) + CD133(+) BMSC administration
Number of subjects: 13
Study: 15126003

Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation group (low-intensity exercise program for an average of 12.0+/‐2.4 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no exercise advice)
Number of subjects: 44
Study: 11641575

Group type: EXPERIMENTAL
Intervention: Chemo-mechanical method (Carisolv system)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Mechanical method (conventional spoon excavators)
Number of subjects: 66
Study: 8997547

Group type: EXPERIMENTAL
Intervention: Nicergoline 30 mg b.i.d.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 7967862

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (methronidazol and gentamicin, single preoperative dose)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lavage of the surgical wound with physiologic serum
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 141
Study: 2442993

Group type: EXPERIMENTAL
Intervention: Indecainide (50 mg every 6 hours, increased to a maximum of 100 mg every 6 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Quinidine (200 mg every 6 hours, increased to a maximum of 400 mg every 6 hours)
Number of subjects: 19
Study: 31539601

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management Mobile Health application (CBSM mHealth) - 10 weekly modules
Number of subjects: 30

Group type: COMPARATOR
Intervention: Generic healthy lifestyle app
Number of subjects: 30
Study: 30352647

Group type: EXPERIMENTAL
Intervention: 4300 m at -10°C (HC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: thermo-neutral sea level (SL)
Number of subjects: 10
Study: 27722772

Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 64
Study: 24047121

Group type: EXPERIMENTAL
Intervention: NIPPV (unsynchronized nasal intermittent positive pressure ventilation)
Number of subjects: 67

Group type: COMPARATOR
Intervention: NCPAP (nasal continuous positive airway pressure)
Number of subjects: 67
Study: 24349392

Group type: EXPERIMENTAL
Intervention: Adaptive Intervention (AI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static Intervention (SI)
Number of subjects: 20
Study: 20598983

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 20063

Group type: COMPARATOR
Intervention: No worsening renal function
Number of subjects: 20063
Study: 18160192

Group type: EXPERIMENTAL
Intervention: Nurse-led brief motivational intervention
Number of subjects: 194

Group type: COMPARATOR
Intervention: Leaflet about alcohol misuse
Number of subjects: 194
Study: 17052633

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Diclofenac 25 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 14602746

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg) and vitamin D (400 IU) supplementation twice daily for 1 year
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Number of subjects: 192
Study: 10799375

Group type: EXPERIMENTAL
Intervention: 10 days of supplementation (1.67 MJ/d and 30 g protein/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Young supplemented subjects
Number of subjects: 17
Study: 8636459

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.06% triclosan
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 10
Study: 7910120

Group type: EXPERIMENTAL
Intervention: (R/S)‐propafenone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (S)‐propafenone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (R)‐propafenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: (R/S)‐propafenone, (S)‐propafenone, (R)‐propafenone
Number of subjects: 0
Study: 2888692

Group type: EXPERIMENTAL
Intervention: 120 mg terfenadine once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: 60 mg terfenadine twice daily
Number of subjects: 191
Study: 30829097

Group type: EXPERIMENTAL
Intervention: Social-media-based support through a smartphone application, text messaging, and e-mail for one menstrual cycle
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no social-media-based support)
Number of subjects: 64
Study: 30954146

Group type: EXPERIMENTAL
Intervention: d‐PTFE membrane (test group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No biomaterial (control group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 26912729

Group type: EXPERIMENTAL
Intervention: Strong for Life (SFL) resistance exercise intervention
Number of subjects: 42
Study: 24255130

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Type III collagen synthesis
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Type I and III collagen synthesis markers
Number of subjects: 42
Study: 22546885

Group type: EXPERIMENTAL
Intervention: Baseline Q waves
Number of subjects: 4341

Group type: COMPARATOR
Intervention: Symptom onset three hours or less before PCI and no baseline Q waves
Number of subjects: 4341
Study: 21058605

Group type: EXPERIMENTAL
Intervention: Magical film
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nonmagical film
Number of subjects: 2
Study: 17138832

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) with 3 g/day L-carnitine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (Con) with 3 g/day L-carnitine
Number of subjects: 22
Study: 15855571

Group type: EXPERIMENTAL
Intervention: 5 microg subcutaneous exenatide b.i.d.
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: 10 microg subcutaneous exenatide b.i.d.
Number of subjects: 733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: 5 microg and 10 microg exenatide
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: 10 microg exenatide
Number of subjects: 733

Group type: EXPERIMENTAL
Intervention: 5 microg exenatide
Number of subjects: 733
Study: 12390212

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9714692

Group type: EXPERIMENTAL
Intervention: CD3(+) T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD19(+) B lymphocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4/CD8 ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4(+)CD28(+) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HLA-DR expression
Number of subjects: 0
Study: 8313807

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during normoglycemia
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous amino acids (Vamin 18, 250 mg protein/kg/hr) during hyperglycemia
Number of subjects: 6
Study: 3136094

Group type: EXPERIMENTAL
Intervention: Misoprostol 400 micrograms twice daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 71
Study: 30196883

Group type: EXPERIMENTAL
Intervention: WCC training (6-hour, single-day teacher training)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: WCC training plus technical assistance (TA)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Delayed training (control)
Number of subjects: 63
Study: 28276086

Group type: EXPERIMENTAL
Intervention: Home-but not Alone mobile-health application educational programme
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 250